Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Inhibitors that target key components of this pathway, including PI3K, AKT and mammalian target of rapamycin (mTOR), are being actively developed. Some of them have reached clinical trials in ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its ...